purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation teva earnings call period ending december image source motley fool teva pharmaceutical industry teva q earnings calljan etcontents prepared remark question answer call participant prepared remark operatorhello welcome fourthquarter fullyear teva pharmaceutical industry earnings conference call name alex coordinating call today operator instruction hand host ran meir head investor relation please go aheadran meir senior vice president investor relation thank alex thank everyone joining u today hope opportunity review press release issued earlier morning copy press release well copy slide presented call found website tevapharmcom please review forwardlooking statement slide additional information regarding statement nongaap financial measure available earnings release sec form k q begin today call richard francis tevas ceo provide overview tevas fullyear result business performance recent event focus priority going forward drshould invest teva pharmaceutical industry right buy stock teva pharmaceutical industry consider motley fool stock advisor analyst team identified believe best stock investor buy teva pharmaceutical industry one stock made cut could produce monster return coming year stock advisor provides investor easytofollow blueprint success including guidance building portfolio regular update analyst two new stock pick month stock advisor service tripled return sp since see stock stock advisor return january eric hughes head rd chief medical officer discus progress innovative pipeline cfo eli kalif follow reviewing fourthquarter financial result detail providing overview tevas financial outlook please note today call run approximately one hour turn call richard richard richard francis president chief executive officer thank ran welcome everybody thank joining call today transformational year teva launched pivot growth strategy get teva back growth pleased say exactly moving next slide go back slide please would like remind pivot growth strategy based four pillar deliver growth engine step innovation create generic powerhouse focus business delivering four pillar go presentation today obviously saw today decided divest tapi business go detail later presentation walk number slide pleased say said got back growth teva would also like highlight number include sanofi upfront payment part collaboration ongoing development commercialization tla tevas growth sale revenue billion take sanofi would adjusted ebitda nongaap eps free cash flow also pleased say made progress net debt ebitda stand next slide want go bit detail driving performance pleased say innovative business performed well austedo particular grew strongly ajovy continues show impressive performance growth regard generic business saw solid performance europe growing international market pleased see stabilization north american generic business well going bit detail driving behind number start austedo next slide austedo hit billion guidance gave yous strong trx contributing pleased performance show clearly highlight benefit additional resource put behind brand extra capability built give confidence move next slide reaffirm guidance hit billion step direction guidance giving billion revenue number worth pointing remembering significant amount patient people suffering tardive dyskinesia go undiagnosed launched directtoconsumer campaign early january help raise awareness give people opportunity help therapy moving newest member family uzedy good growth planned uzedy giving guidance million possible work drove awareness access make good progress across commercial payer well medicare medicaid ensuring get onto formulary many hospital awareness good technical difficulty feedback product profile fact fit patient profile seeing would also highlight size market billion market growing think uzedy contribute growth year coming year well move last member innovative portfolio ajovy pleased continued momentum growth see growth across region many geography gaining market share show true competitiveness teva based good performance giving guidance billion ajovy another aspect delivery growth engine strategy biosimilar portfolio would like move would like highlight fact launching five biosimilars next four year opportunity contribute top bottomline growth come humira awaiting fda inspection result partner site based partner alvotech site based iceland based successful outcome aim launch biosimilar humira year moving second pillar pivot growth strategy pipeline colleague eric walk greater detail strategy focus mentioned really moved needle olanzapine completed recruitment starting expect result h year icssaba entered clinic q last year see attractive market think differentiated product one competitor good momentum around tla excited partnership sanofi really maximize asset going forward moving third pillar strategy generic making generic powerhouse said past based three specific area focused making sure right portfolio market executed commercial team focusing pipeline bring highvalue product grow top bottom line market time often also optimizing network actually efficiency network talk pipeline wanted highlight work done network closed three site continue rationalize optimize also kicked operational excellence plan aim reduce cog allow u drive gross margin expansion let talk bit pipeline made progress see come complex generic think leading position yous across multiple technology platform launch complex direct product launched excited launching see highlighted slide green circle number already launched opportunity u drive growth offset price erosion obviously yous market move final pillar focusing capital today announced intention divest teva api line pivot strategy allow tapi realize full potential world api market valued billion subsequently allowed teva focus capital driving pivot growth strategy primarily focused innovative generic portfolio moving next slide give guide milestone pretty much keep executing strategy driving innovative portfolio see billion austedo keep driving pipeline clinic bring market soon possible work driving efficiency launch manufacturing base generic business obviously work year divest tapi end year start next moving final slide would like announce healthy future plan continuation esg journey teva teva focused three main area divide healthy people making sure create access medicine across planet making sure people medicine needed right time also making sure inclusive diverse culture teva secondly healthy planet really teva stepping helping minimize impact global warming many initiative put place finally healthy technical difficulty everything teva compliant highest ethical standard hand portion presentation colleague eric hugheseric hughes chief medical officer head research development thank richard moving slide ajovy know physician choose ajovy safety efficacy well convenient autoinjector monthly dosing technical difficulty today excited show recent data produced two realworld evidence study pearl finesse showing durability ajovy migraine chronic disease durability response important see study day free migraine maintained two year starting ajovy important translates simple reduction monthly migraine really eight full day patient achieve day without migraine month patient get back week life without migraine important moving slide uzedy richard mentioned excited get approval last year launch uzedy also happy show durability uzedy well following subject pivotal study show quality life patient maintained week also slightly improved important well patient schizophrenia patient long duration disease short duration disease show long acting injectable could actually maintain improve quality life important longacting injectables believe important maintain exposure patient blood risperidone think important happy see durability response moving austedo one thing important austedoand richard mentioned much room grow access patient tardive dyskinesia one thing need make sure easy convenient use austedo possible know realworld evidence patient without titration pack achieve dose range necessary get good technical difficulty ran study technical difficulty pleased see subject could finish titration pack adherent important getting titration pack easily simply patient get patient right dose ring make sure get patient right efficacy hope translates durability adherence longterm treatment important glad see work well patient finally want review milestone rd organization well enrollment phase ii study tla accelerating looking forward phase ii interim analysis second half fully enrolled olanzapine lai phase iii globally full clinical package efficacy safety second half anti il program finishing phase sad mad study healthy volunteer present data second half year also finish enrollment proofofconcept study celiac patient end year excited look forward firstinhuman dosing antipd il program first half year finally actively enrolling phase iii study icssaba looking forward result second half pas eli kalifeli kalif executive vice president chief financial officer thank eric good morning good afternoon everyone begin review financial result main focus fourthquarter performance followed nongaap outlook important assumption behind beginning slide would like remind everyone october teva entered exclusive collaboration sanofi develop commercialize tevas antitla asset per term collaboration agreement teva received upfront payment million fourth quarter recognized license arrangement revenue upfront payment positive contribution million revenue free cash flow adjusting certain transactionsrelated cost payment positive contribution technical difficulty approximately million throughout presentation discussing result quarter full year reported also want draw attention disclosure included press release morning regarding revision certain gaap financial metric correct error related contingent consideration liability provision impact nongaap result either year starting q gaap performance revenue fourth quarter billion increase yous dollar local currency term compared fourth quarter increase mainly driven upfront payment mentioned sale certain product right europe segment continued strong growth austedo higher revenue generic product international market partially offset lower revenue generic product distribution business north america copaxone q recorded gaap operating income million compared operating loss million quarter last year increase operating income mainly due goodwill impairment charge fourth quarter higher gross profit technical difficulty year partially offset higher impairment restructuring item fourth quarter net income million gaap earnings per share higher last year mainly driven higher operating income explained turning slide see nongaap adjustment fourth quarter notable adjustment quarter included contingent consideration expense million mainly related change estimated future royalty payment connection generic revlimid moving slide review nongaap performance mentioned earlier fourthquarter revenue approximately billion annual revenue billion increase yous dollar local currency term compared excluding contribution upfront payment regarding antitla collaboration revenue growth let u move pl starting gross profit margin nongaap gross profit margin compared q increase gross margin mainly due upfront payment mentioned favorable portfolio mix well sale certain product right europe part portfolio rationalization partially offset higher cost related inflationary macroeconomic pressure excluding impact upfront payment nongaap gross profit margin would consistent level q slightly expectation mainly due timing effect related certain element cost associated inventory consumption portfolio mix betterthanexpected performance lowmargin distribution business well unfavorable impact hedging activity overall saw sustainable improvement gross profit margin since first quarter stabilization margin second half going forward expect gross margin continue improve driven continuous improvement portfolio mix strong growth innovative portfolio well continuation optimization program initiated expected nongaap gross profit margin full year similar expect gross margin gradually improve throughout year moving nongaap operating margin q compared q increase mainly driven higher nongaap gross profit margin explained well lower operating expense percentage revenue absolute basis higher operating expense quarter related higher investment rd sale marketing line pivot growth strategy partially offset efficiency technical difficulty ended quarter earnings per share compared q mainly driven higher operating income turning free cash flow slide free cash flow fourth quarter billion compared billion q addition technical difficulty sale driven technical difficulty ebitda item partially offset sale account receivable yous facility fourth quarter fourth quarter also initiated first payment nationwide settlement connection opioid litigation increased total payment legal settlement approximately million compared q overall full year free cash flow billion compared billion turning slide continue make strong progress term reducing debt net debt end q billion compared billion end gross debt billion compared billion end decrease gross debt mainly due billion inaudible repaid maturity partially offset million exchange rate fluctuation q repaid full million billion revolving credit facility december st today amount outstanding revolver result net debt ebitda also improved coming time q part capital allocation strategy expect net debt reduction continue continue progress toward longterm target two time net debt ebitda end let u turn attention nongaap outlook richard mentioned pivotal year teva throughout year product around world worked hard execute pivot growth strategy made deliberate choice began investing growth driver promising pipeline also navigating addressing impact macroeconomic geopolitical headwind move remain focused continue execute longterm strategy mind began total revenue expect billion billion compared represents growth excluding million upfront payment received related tla asset richard mentioned earlier revenue growth driven continued strong momentum innovation innovative portfolio stabilized generic business coming nongaap operating profit expect gross margin gradually improve throughout continue execute pivot growth strategy continue make deliberate investment innovative portfolio progress key pipeline asset drive short longterm growth company mind expect operating expense approximately full year including rd expense revenue result nongaap operating income expected billion billion nongaap adjusted ebitda expected billion billion growing level excluding effect upfront payment expect finance expense approximately billion line level looking tax rate expect nongaap tax rate technical difficulty percent slightly higher tax rate benefited partially due intellectual propertyrelated integration plan carryforward loss brings u expect nongaap earnings per share range expect free cash flow range billion billion technical difficulty provide quarterly guidance thought helpful share thinking progression throughout year overall based expectation today expect revenue earnings progress gradually year revenue second half slightly higher first half nongaap margin also expected technical difficulty throughout year line revenue trajectory well improvement optimization program initiated concludes review tevas result fourth quarter fiscal year hand back richard summaryrichard francis president chief executive officer thank eli go next slide yes would like reiterate financial target revenue growth mid single digit operating margin net debtadjusted ebitda two time cashtoearnings ratio reconfirming move forward gain confidence pivot growth strategy moving final slide reiterate pivot growth strategy drive growth main accelerate growth return growth accelerate believe built momentum eric pipeline product coming market also start see biosimilars gain traction well based earlier comment clear see gaining momentum pivot growth executing hand operator take question thank attention question answer operatorthank operator instruction first question today come glen santangelo jefferies line open please go aheadglen santangelo jefferies analyst hi thanks taking question eli wanted follow guidance couple thing sticking look like assuming midpoint revenue going little bit le assuming ebitda midpoint almost think heard richard correctly assuming gross margin going perhaps due product mix seems like forecasting much bigger ramp operating expense could wonder could sort flesh little bit coming sale marketing side greater rd spend maybe quick followup thanksrichard francis president chief executive officer eli think question directed youeli kalif executive vice president chief financial officer thanks glen question first looking midpoint billion compared number end excluding upfront payment mean looking growth midpoint top line far related dynamic operating margin see keep growing opex mentioned working range mean rd stabilization around ga sale marketing around mean part growth enable u keep investing business question line guidance look excluding upfront paymentglen santangelo jefferies analyst ok maybe could sort follow want make sure understand revenue guidance little bit gave u lot piece helpful want clear seeing term generic business mean could see obviously cut copaxone assumption fair amount trying figure rest offset know bunch big launch generic side korlym teriparatide forteo sort flesh little bit expecting generic business clear seeingrichard francis president chief executive officer hi glen richard thanks question yes sort reiterate think question directed north america generic business highlight fact european international market business expect continue growing well line come back question yes number launch coming pleased made progress would like highlight coming competition well need take account forecasting obviously launch product part aim offset price degradation see every year yous netnet see stabilization north american business going forward continue build improve launch supply chain believe medium long term drive business back growthglen santangelo jefferies analyst ok thank richard francis president chief executive officer thanks questionoperatorthank next question come ash verma ubs line open please go aheadash verma ubs analyst hi thanks taking question clarify guidance including partnership accounting sanofi upfront specific amount expecting receive believe next set milestone phase iii initiation believe would happen year first one second curious like north america generic mean q print seems like step franchise run rating kind benefit generic revlimid starting see change price stabilization narrative thanksrichard francis president chief executive officer hi ash thanks question tackle regard sanofi correct receive payment based eric highlighted successful interim analysis year phase ii data tla move phase iii trigger milestone sanofi anything go north america generic question couple thing try answer question part think saw fact really significant revenue revlimid quarter worth noting think business included truxima biosimilar business know performed well generated good revenue number year obviously declining steadily factor thing factor think comment see stabilization north america generic business going forward think stand true based number launch coming think ability offset significant amount price erosion see yearly yous think way think stabilization quarterly change really primarily driven bit portfolio bit relation biosimilar single product truxima hopefully help ashash verma ubs analyst thanksoperatorthank next question come jason gerberry bank america jason line open please go aheadjason gerberry bank america merrill lynch analyst hey guy thanks taking question question biosimilars wondering think could potentially make hay biosimilar humira get interchangeability designation february approval leverage get like big chunky contract preferred biosimilar supplier know noninterchangeable high concentrate struggled get share maybe carry right mean question stelara pbm biosimilar space sort broken innovator playing rebating game could leverage like portfolio play like interchangeable humira layering top stelara kind wondering overall perspective observed pbm biosimilars whether think opportunity thanksrichard francis president chief executive officer yes thanks jason thanks question biosimilar one starting biosimilar humira really obviously depends fda given successful inspection partner alvotech facility iceland happen hopefully know relatively soon give u opportunity launch think obviously lot play still slope regard penetration biosimilars said lot uncertain variable get fda approval site able launch timing launch point penetrate pbms would say good conversation people interested hearing product come market think lot based product profile interchangeability autoinjector see opportunity way always characterized opportunity short medium long term think humira could add revenue business year think definitely think direction travel clear biosimilars think humira define happens going forward think humira inaudible regard actually get product approved think talk stelara stelara think learned biosimilars quite long time one product set precedent next one think stelara many thing different around one lot le competitor one two clear line sight going approved launched february optimistic see sizable asset see something generate significant revenue regard speed uptake see play think important thing teva hanging fact product need come market deliver quick revenue portfolio play asset bring market mentioned got five going launch think generate good return drive top line bottom line specific one generate revenue think want unpredictability seen last year hope way answer question jasonjason gerberry bank america merrill lynch analyst got thank youoperatorthank next question come umer raffat evercore line open please go aheadumer raffat evercore isi analyst hi guy thanks taking question couple may first maybe design uc crohn study baseline expecting mild moderate moderatetosevere patient percentage maybe biologics experienced expectation secondly noticed crohn study endpoint using endoscopic response actually different fda want coprimary couple secondary endpoint cdai le endoscopic remission fda focused coprimary really focused secondary endpoint primary basis determining crohn trial looked finally could give quick update recent generic launch korlym given interest launch going date thank youeric hughes chief medical officer head research development thank umer richard take question mind regard inclusion criterion study focused mild moderate patient see coming study right typical study run recently happy see inclusion criterion study able enroll well fact inclusion criterion study execution got accelerated pace ulcerative colitis actually crohn patient well encouraging see one first wellcontrolled placebocontrolled study crohn new moa criterion focused patient coming study right regard endpoint endpoint included study fdaaccepted study endpoint discussed fda pretty common across different study think one criterion pay attention count clinical endpoint might change see placebo response compared active confident way designed study done conjunction fda final question korlym know richard want take thatrichard francis president chief executive officer yeah take eric thanks question umer launched commenced launched think week ago launched market think answer questionumer raffat evercore isi analyst thank muchrichard francis president chief executive officer thanks umeroperatorthank next question come david amsellem piper sandler line open please go aheaddavid amsellem piper sandler analyst hey thanks one question austedo one uzedy austedo wanted get sense level sale marketing investment dtc investment thinking product longer term certainly competitor spent pretty heavily promoting supporting ingrezza think tie longterm thinking regarding trajectory operating margin number one number two uzedy think mentioned million wanted drill patient coming patient switching lais naive lais getting switch say invega one invega product wanted get sense business uzedy coming early day thank yourichard francis president chief executive officer thanks david thanks question austedo right invested significantly austedo built capability sale force bringing pharmaceutical expertise done think significant contributor acceleration product continued performance aim make sure competitive maximizing revenue austedo also knowing last part question want driving improvement operating margin see ability definitively austedo sale marketing put talk billion going major contributor u driving top line particularly op modeled extensively regard uzedy seeing right highlight relatively small data seeing considerable amount patient coming risperidone lot patient going straight oral longacting uzedy come choosing longacting risperidone significant proportion going uzedy well think highlight think eric pointed much physician like product profile primarily fact get therapeutic level within six hour schizophrenic episode really critical think seeing enthusiasm taking enthusiasm access converting script hopefully answer question daviddavid amsellem piper sandler analyst yes helpful thank yourichard francis president chief executive officer thank youoperatorthank next question come chris schott jpmorgan chris line open please go aheadchris schott jpmorgan chase company analyst hi great thanks much two question maybe following opex comment obviously stepped opex seeing really nice growth core driver pipeline progressing trying get hand around opex beyond guess kind range seeing year good level next year actually reaching absolute spend level maybe think opex leverage kind looking beyond second question little bit color international generic growth driver seemed like business particularly strong think comment assuming similar growth year would love little bit color dynamic seeing market thank yourichard francis president chief executive officer ok thanks question chris first one tag team bit eli think give sort high level opex one thing realized teva significant opportunity front u innovative portfolio market uzedy austedo ajovy great pipeline eric talked really important invest optimize bring market soon possible absolutely commit believe going hit margin investing allows u change trajectory product speed bring market olanzapine potentially end early obviously changed portfolio mix gross margin deliver obviously fall op thought carefully invest actually start see significant pickup bottom line maybe give specific eli welleli kalif executive vice president chief financial officer thanks richard thanks chris question continue richards answer term absolute number see one much expand dollarwise onwards grow revenue course percentage go currently year range also would like remind certain element rd sale marketing still considered viable element level control term prioritization timing level controllable item perspectiverichard francis president chief executive officer second question asked chris around international pleased see seen good growth continued ambition primarily driven prioritization continued market expansion really making sure focus market deliver team done tremendous job making sure prioritization resource go market drive top line also bottom line subcomponent pivot growth strategy hoping answer question chris thank themoperatorthank next question come balaji prasad barclays line open please go aheadbalaji prasad barclays analyst hi good morning everyone thank question couple firstly q performance outlook pretty strong midpoint higher highest bloomberg estimate see look like drowned aftermath restatement going stock reaction please provide color happened implication onetime risk statement secondly partnership alvo considering teva greater involvement biosimilar facility inspection looking fda letter alvotech received related fda observing frequent sanitation operator help u understand easy difficult address issue general normal resolution fda accept observation thank yourichard francis president chief executive officer thanks balaji appreciate question start second question hand first question eli regard alvotech partnership correct heavily involved helping think said past think around fda inspection year across site proficient dealing given guidance help alvotech think regard observation seen one observation think u considered relatively small observation caution fda entirely give view whether allows u allows alvotech site cleared think good inspection show huge amount work done site make approvable fda cautioned fda approve site first would say think alvotech put good position see play answer first question hand back elieli kalif executive vice president chief financial officer thanks balaji question yes part preparation consolidation statement determined error single contingent consideration liability related expense connected estimated future royalty payment error resulted exclusion payment related royalty way fair value reimbursement need recalculate set materiality error determined error material one period revision number restatement actually implement financials would like mention error impact nongaap result well impact total cash flow operating activity financing activity investing activity speak progress process implement remediation plan address internal controlbalaji prasad barclays analyst thank yourichard francis president chief executive officer thank balaji operatorthank next question come nathan rich goldman sachs line open please go aheadnate rich goldman sachs analyst great good morning thanks question wanted follow north america generic business think richard response earlier question talked stabilization north america generic business guess mean annualizing q revenue run rate flat yearoveryear relative comment maybe longerterm question pricing pbms talked moving kind costplusdrug reimbursement curious would expect longerterm impact generic pricing industryrichard francis president chief executive officer hi nathan thank question think come north american one thing talk think talked early pivot growth want first stabilize yous generic business particular get back growth think see number launch opportunity whether tip growth whether tip back flat stabilization see play reason hesitation absolutely definitive talked around pricing erosion next week also next week next year also number launch many competitor come play lot variable within think u stability building getting back growth think thoughtful communicate way think regard pricing said pbms saying welcome anybody start look generic pricing make sustainable think right challenging environment continues value generic bring healthcare industry hospital society reflected price sell think creates challenging environment think probably led pbms payer thinking actually supply challenge mitigate think raised discussion would solution think many others could also suggest think ultimately price creates sustainability allows u invest launch capital manufacturing site think requires people step back understand bit take achieve good fact conversation think silver bullet necessarily improve market thanks question nathannate rich goldman sachs analyst thank youoperatorthank next question come jason gerberry bank america line open please go aheadjason gerberry bank america merrill lynch analyst hey thanks taking followup curious comment inaudible margin planned divestiture think million external million internal revenue wondering think profitable business try like think potential valuation olanzapine lai program guy give update regarding number injection without pd signal next update second half pivotal topline update thanksrichard francis president chief executive officer thank jason thanks question coming back think regard tapi think idea going margin hand eli whole think pretty neutral regard margin think impacting margin positive negative way probably simplest way think one anything add elieli kalif executive vice president chief financial officer think anything addrichard francis president chief executive officer ok going olanzapine hand one eric maybe get specific fact fully recruited study maybe many injection haderic hughes chief medical officer head research development give uptominute data right patient study fully enrolled globally point date got injection completed pd point total target want inaudible package submission well way monitor closelyrichard francis president chief executive officer thanks eric thanks question jasonjason gerberry bank america merrill lynch analyst yes thank youoperatorthank next question come oleksiy soroka ing line open please go aheadoleksiy soroka ing financial market analyst yes hi thank taking question regard debt plan refinancing upcoming maturity including bondsrichard francis president chief executive officer thank oleksiy question eli could take oneeli kalif executive vice president chief financial officer yes thanks question yes looking coming year maturity around million due april another approximately million due october euro maturity pretty would say positioned well manage maturity organic free cash flow tower around billion around october allowing u enough time consider need make next refinancing constantly looking market term capacity trend calculating strategy around currently would say specific need go earlyoleksiy soroka ing financial market analyst would expect deal peak mentioned october year start prefunded iteli kalif executive vice president chief financial officer yes really depends dynamic weighted average would say maturity need turn level threeplus percent maturity market range really depends one evolves need actually consider capital allocation term interest expense timing mentioned constantly looking one usually would like go month ahead order address maturity think kind enough time still reviewing strategy around itoleksiy soroka ing financial market analyst ok right thank yourichard francis president chief executive officer thanks questionoperatorthank next question come madison aron jpmorgan line open please go aheadmadison aron jpmorgan chase company analyst hi thanks taking question slidepage generic pipeline include nexplanon one technology target walk u planning anda filing planning could give u detail thank yourichard francis president chief executive officer hi madison thanks question glad noticed slide numerous complex generic bringing market regard obviously quite competitive environment like go much specific nature think highlighting give good insight coming think wanted show fact broad portfolio across number technology aim competitive reason really want get strategy detail around hopefully understand thatmadison aron jpmorgan chase company analyst thank youoperatorthank time currently question hand back richard francis remarksrichard francis president chief executive officer thank thank everybody dialing appreciate interest teva appreciate question look forward catching many next couple day obviously look forward speaking quarter earnings later year thank muchoperatoroperator signoff duration minutescall participantsran meir senior vice president investor relationsrichard francis president chief executive officereric hughes chief medical officer head research developmenteli kalif executive vice president chief financial officerglen santangelo jefferies analystash verma ubs analystjason gerberry bank america merrill lynch analystumer raffat evercore isi analystdavid amsellem piper sandler analystchris schott jpmorgan chase company analystbalaji prasad barclays analystnate rich goldman sachs analystoleksiy soroka ing financial market analystmadison aron jpmorgan chase company analyst teva analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position stock mentioned motley fool disclosure policy